drugset / Trial / NCT02669862

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862

Phase 2 Completed 98 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.

Timeline

Start
2015-12-21
Primary completion
2016-09-16
Completion
2016-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 40 %
Subject Hydrogen Peroxide Small molecule 45 %

Indications